The purpose of this contract, entitled Inhaled Gentamicin Dry-Powder Formulation for Postexposure Prophylaxis and Treatment of Aerosolized Pneumonic Plague and Tularemia, is to develop an inhaled gentamicin, currently the first-line therapy for pneumonic plague and tularemia, as a dry powder formulation in multi-dose inhalers for non-invasive, post-exposure prophylaxis and treatment resulting from aerosol exposure.
